Iodine-131 Therapy for Hyperthyroidism Prescribed by Endocrinologist – Our Preliminary Experience

 

 Buy Article Permissions and Reprints

Abstract

Introduction: Radioiodine (I-131) is a useful therapeutic modality of hyperthyroidism when medical therapy fails. Traditionally, the nuclear physicians undertake the prescription of I-131 therapy. However, endocrinologists are increasingly being recognized for their competence in prescribing individualized doses of I-131 for the treatment of various thyroid disorders.

Methods: In this pilot prospective study, we collaborated with our nuclear medicine colleagues to determine the outcomes of 80 patients with hyperthyroidism who underwent I-131 ablation as prescribed by the endocrinologist. Doses administered were based primarily on thyroid volume with adjustments contingent on adverse factors, and fixed assumptions on target absorbed dose (R) and uptake (U) were used. Seventy-three had Graves’ disease (GD) and seven had toxic nodular goitre (TNG) or toxic adenomas (AFTN). Therapeutic success was defined as achievement of hypothyroidism or euthyroidism.

Results: 95.9 percent (70 of 73) of GD patients and 85.7 percent (6 of 7) of those with TNG/AFTN achieved successful outcomes after a single dose of endocrinologist-directed I-131 therapy. More than 50 percent of patients became hypothyroid by three months and about two-thirds became hypothyroid by six months post I-131 therapy.

Conclusion: Our results indicate that the success rate of endocrinologist-directed I-131 therapy exceeds 95 percent with a single dose and compares favourably with nuclear physician-directed therapy outcomes.

References

• 1 Akyat R, Rezai K, Seabold JE. et al . Four- to twenty-four-hour uptake ratio: an index of rapid iodine-131 turnover in hyperthyroidism.  J Nucl Med. 1996;  37 1815-1819
  PubMedGoogle Scholar
• 2 Alexander EK, Larsen PR. High dose of (131)-I therapy for the treatment of hyperthyroidism caused by Graves’ disease.  J Clin Emdocrinol Metab. 2002;  87 1073-1077
  CrossrefPubMedGoogle Scholar
• 3 Allahabadia A, Daykin J, Sheppard MC. et al . Radioiodine treatment of hyperthyroidism – prognostic factors for outcome.  J Clin Endocrinol Metab. 2001;  86 3611-3617
  CrossrefPubMedGoogle Scholar
• 4 American Association of Clinical Endocrinologists (AACE) . , Website – http://www.aace.com/edu/symposia.php
• 5 Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study.  J Clin Endocrinol Metab. 2001;  86 3488-3493
  CrossrefPubMedGoogle Scholar
• 6 Bartalena L, Marcocci C, Bogazzi F. et al . Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism.  N Engl J Med. 1989;  321 1349
  Google Scholar
• 7 Bartalena L, Marcocci C, Bogazzi F. et al . Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy.  N Engl J Med. 1998;  338 73-78
  Google Scholar
• 8 Baskin HJ. Who should treat? Endocrinologists and radioiodine.  Thyroid. 1997;  7 233-234
  CrossrefPubMedGoogle Scholar
• 9 Braga M, Walpert N, Burch HB. et al . The effects of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial.  Thyroid. 2002;  12 135-139
  CrossrefPubMedGoogle Scholar
• 10 Chiovato L, Fiore E, Vitti P. et al . Outcome of thyroid function in Graves’ patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.  J Clin Endocrinol Metab. 1998;  83 40-46
  CrossrefPubMedGoogle Scholar
• 11 Erem C, Kandemir M, Hacihasanoglu A. et al . Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome.  Endocrine. 2004;  25 55-60
  CrossrefPubMedGoogle Scholar
• 12 Eschmann SM, Thelen MH, Dittmann H. et al . Influence of short-term interruption of antithyroid drugs on the outcome of radioiodine therapy of Graves’ disease: results of a prospective study.  Exp Clin Endocrinol Diabetes. 2006;  114 222-226
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Feitelberg S, Caunitz PS, Silver S. et al . Hyperthyroidism treated with radioactive iodine.  Arch Intern Med. 1950;  85 71
  PubMedGoogle Scholar
• 14 Hertz S, Roberts A. Application of radioactive iodine in therapy of Graves’ disease.  J Clin Invest. 1942;  21 624
  PubMedGoogle Scholar
• 15 Kung AW, Choi P, Lam KS. et al . Discriminant factors affecting early outcomes of radioiodine treatment for Graves’ disease.  Clin Radiol. 1990;  42 52-54
  CrossrefPubMedGoogle Scholar
• 16 Marinelli LD, Quimby EH, Hine G. Dosimetry of radioactive isotopes: biological observations and practical applications.  Strahlentherapie. 1950;  81 587-594
  PubMedGoogle Scholar
• 17 Peters H, Fischer C, Bogner U. et al . Radioiodine therapy of Graves’ hyperthyroidism: standard vs. calculated 131-iodine activity. Results from a prospective, randomized, multicenter study.  Eur J Clin Invest. 1995;  25 186-193
  CrossrefPubMedGoogle Scholar
• 18 Reinhardt M, Emrich D, Krause T. et al . Improved dose concept for radioiodine therapy of multifocal and disseminated functional thyroid autonomy.  Eur J Endocrinol. 1995;  132 550-556
  CrossrefPubMedGoogle Scholar
• 19 Reinhardt MJ, Brink I, Joe AY. et al . Radioiodine therapy in Graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.  Eur J Nucl Med Mol Imaging. 2002;  29 1118-1124
  CrossrefPubMedGoogle Scholar
• 20 Shapiro B. Optimization of radioiodine therapy of thyrotoxicosis: what have we learned after 50 years?.  J Nucl Med. 1993;  34 1638-1641
  PubMedGoogle Scholar
• 21 Tallstedt L, Lundell G, Torring O. et al. . Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism.  N Engl J Med. 1992;  326 1733
  Google Scholar
• 22 Tavintharan S, Sundram FX, Chew LS. Radioiodine (I-131) therapy and the incidence of hypothyroidism.  Ann Acad Med Singapore. 1997;  26 128-131
  PubMedGoogle Scholar
• 23 Tominaga T, Yokoyama N, Nagataki S. et al . International differences in approaches to I-131 therapy for Graves disease: case selection and restrictions recommended to patients in Japan, Korea and China.  Thyroid. 1997;  7 217-220
  CrossrefPubMedGoogle Scholar
• 24 Turton DB, Silverman ED, Shakir KM. Time interval between the last dose of propylthiouracil and I-131 therapy influences cure rates in hyperthyroidism caused by Graves’ disease.  Clin Nucl Med. 1998;  23 810-814
  CrossrefPubMedGoogle Scholar
• 25 Ustun F, Yuksel M, Durmus-Altun G. et al . The incidence of recurrence and hypothyroidism after radioiodine treatment in patients with hyperthyroidism in Trakya, a mild iodine deficiency area, during the period 1991–2003.  Ann Nucl Med. 2005;  19 737-742
  CrossrefPubMedGoogle Scholar
• 26 Walter MA, Christ-Crain M, Eckard B. et al . Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine up-take level and post-therapeutic outcome.  Eur J Clin Invest. 2004;  34 365-370
  CrossrefPubMedGoogle Scholar
• 27 Werner SC, Quinby EH, Schmidt C. Clinical experience in diagnosis and treatment of thyroid disorders with radioactive iodine.  Radiology. 1948;  51 564
  PubMedGoogle Scholar

Correspondence

M. K.-S. LeowMD, PhD, FAMS, FACE, FACP 

Department of Endocrinology

Division of Medicine

Tan Tock Seng Hospital

11 Jalan Tan Tock Seng

Singapore 308433

Phone: (065) 6357/78 81

Fax: (065) 6357/78 71

Email: mleowsj@massmed.org